Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02500407
Title A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | ESP | DEU | CAN | AUS


No variant requirements are available.